Terms: = Prostate cancer AND LMNA, EMD2, 4000, ENSG00000160789, LGMD1B, LDP1, PRO1, LMNC, FPLD, CDDC, HGPS, P02545, LFP, IDC, CMD1A, CDCD1, LMN1, CMT2B1, FPL AND Treatment
73 results:
1. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
2. Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations.
Hu J; Chen X; Sun F; Liu L; Liu L; Yang Z; Zhang H; Yu Z; Zhao R; Wang Y; Liu H; Yang X; Sun F; Han B
Neoplasia; 2024 Apr; 50():100983. PubMed ID: 38417222
[TBL] [Abstract] [Full Text] [Related]
3. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
4. Intraductal prostate cancer Affinity for Lymphatic-Predominant Metastases Through
Bernardino R; Sayyid RK; Lajkosz K; Al-Daqqaq Z; Tiwari R; Cockburn J; Leão R; Metser U; Berlin A; van der Kwast T; Fleshner NE
J Urol; 2024 Apr; 211(4):586-593. PubMed ID: 38299501
[TBL] [Abstract] [Full Text] [Related]
5. A Low or High Physical Activity Level Does Not Modulate prostate Tumor Tissue Protein Synthesis Rates.
Houben LHP; Tuytten T; Holwerda AM; Wisanto E; Senden J; Wodzig WKWH; Olde Damink SWM; Beelen M; Beijer S; VAN Renterghem K; VAN Loon LJC
Med Sci Sports Exerc; 2024 Apr; 56(4):635-643. PubMed ID: 38079310
[TBL] [Abstract] [Full Text] [Related]
6. Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the prostate.
Zhao J; Xu N; Zhu S; Nie L; Zhang M; Zheng L; Cai D; Sun X; Chen J; Dai J; Ni Y; Wang Z; Zhang X; Liang J; Chen Y; Hu X; Pan X; Yin X; Liu H; Zhao F; Zhang B; Chen H; Miao J; Qin C; Zhao X; Yao J; Liu Z; Liao B; Wei Q; Li X; Liu J; Gao AC; Huang H; Shen P; Chen N; Zeng H; Sun G
Cancer Res; 2024 Jan; 84(1):154-167. PubMed ID: 37847513
[TBL] [Abstract] [Full Text] [Related]
7. Limitations of prostate Biopsy in Detection of Cribriform and Intraductal prostate cancer.
Bernardino RM; Sayyid RK; Lajkosz K; Al-Daqqaq Z; Cockburn JG; Chavarriaga J; Abedi S; Leão R; Berlin A; van der Kwast T; Fleshner NE
Eur Urol Focus; 2024 Jan; 10(1):146-153. PubMed ID: 37696743
[TBL] [Abstract] [Full Text] [Related]
8. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 prostate cancer Subtypes.
Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR
Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400
[TBL] [Abstract] [Full Text] [Related]
9. Associations Between Intraductal prostate cancer and Metastases Following Radical prostatectomy in Men With prostate cancer in the Veterans Affairs Database.
Nelson TJ; Kumar A; Nalawade V; Nonato T; Shabaik A; Roma A; Rose BS; McKay RR
Clin Genitourin Cancer; 2023 Aug; 21(4):452-458. PubMed ID: 37095044
[TBL] [Abstract] [Full Text] [Related]
10. Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
Naito Y; Kato M; Kawanishi H; Yamamoto A; Sakamoto F; Hirabayashi H; Kobayashi M; Matsukawa Y; Kimura T; Araki H; Nishikimi T; Kondo A; Yoshino Y; Hashimoto Y; Nakano Y; Tsuzuki T
Prostate; 2023 Mar; 83(4):307-315. PubMed ID: 36420892
[TBL] [Abstract] [Full Text] [Related]
11. VMAT partial arc technique decreases dose to organs at risk in whole pelvic radiotherapy for prostate cancer when compared to full arc VMAT and IMRT.
Bartlett GK; Njeh CF; Huang KC; DesRosiers C; Guo G
Med Dosim; 2023 Spring; 48(1):8-15. PubMed ID: 36319515
[TBL] [Abstract] [Full Text] [Related]
12. The Influence of the Intraductal Carcinoma of the prostate on the Short-Term Oncological Outcomes.
Kalemci S; Kizilay F; Simsir A; Emre Ergun K; Kose T
Arch Esp Urol; 2022 Jun; 75(5):405-409. PubMed ID: 35983810
[TBL] [Abstract] [Full Text] [Related]
13. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.
Kench JG; Amin MB; Berney DM; Compérat EM; Cree IA; Gill AJ; Hartmann A; Menon S; Moch H; Netto GJ; Raspollini MR; Rubin MA; Tan PH; Tsuzuki T; Turjalic S; van der Kwast TH; Zhou M; Srigley JR
Histopathology; 2022 Oct; 81(4):447-458. PubMed ID: 35758185
[TBL] [Abstract] [Full Text] [Related]
14. Clinical significance of idc-P as predictive factor after intensity-modulated radiation therapy.
Aizawa R; Tsuzuki T; Haga H; Nakamura K; Ogata T; Inoue T; Kobayashi T; Akamatsu S; Goto T; Ogawa O; Mizowaki T
Cancer Sci; 2022 Jul; 113(7):2425-2433. PubMed ID: 35514196
[TBL] [Abstract] [Full Text] [Related]
15. [Changes in the penis size of prostate cancer patients after radical prostatectomy and its influencing factors].
Su HC; Gu XF; Zhu Y; Dai B; Qin XJ; Lin GW; Shen YJ; Ye DW
Zhonghua Nan Ke Xue; 2021 Jun; 27(6):522-525. PubMed ID: 34914292
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Features and Clinical Implications of Intraductal Carcinoma of the prostate.
Kang M; Lee H; Byeon SJ; Kwon GY; Jeon SS
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884926
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Outcomes from Dose-Reduced Radiotherapy to the prostate in Elderly Patients with Localized prostate cancer.
Samson N; Khanolkar RA; Quirk S; Quon H; Roumeliotis M; Balogh A; Sia M; Thind K; Husain S; Martell K
Curr Oncol; 2021 Sep; 28(5):3729-3737. PubMed ID: 34677236
[TBL] [Abstract] [Full Text] [Related]
18. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy.
Ramotar M; Chua MLK; Truong H; Hosni A; Pintilie M; Davicioni E; Fleshner NE; Dicker AP; Bristow RG; He HH; van der Kwast T; Den RB; Berlin A
Urol Oncol; 2022 Jan; 40(1):5.e1-5.e13. PubMed ID: 34538726
[TBL] [Abstract] [Full Text] [Related]
19. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Wang Z; Zhu S; Zhao J; Nie L; Chen X; Zhang M; Chen N; Sun G; Chen J; Ni Y; Dai J; Liu Z; Tao R; Zhang X; Zhu X; Zhang H; Liang J; Wang Z; He B; Shen P; Zeng H
Prostate; 2021 Nov; 81(15):1191-1201. PubMed ID: 34435696
[TBL] [Abstract] [Full Text] [Related]
20. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
Zhao J; Sun G; Zhu S; Dai J; Chen J; Zhang M; Ni Y; Zhang H; Shen P; Zhao X; Zhang B; Pan X; Nie L; Yin X; Liang J; Zhang X; Wang Z; Zhu X; Liao B; Liu Z; Armstrong CM; Gao AC; Huang H; Chen N; Zeng H
BJU Int; 2022 Mar; 129(3):345-355. PubMed ID: 34185954
[TBL] [Abstract] [Full Text] [Related]
[Next]
